Veracyte Inc
NASDAQ:VCYT

Watchlist Manager
Veracyte Inc Logo
Veracyte Inc
NASDAQ:VCYT
Watchlist
Price: 39.59 USD 1.67% Market Closed
Market Cap: 3.1B USD
Have any thoughts about
Veracyte Inc?
Write Note

Veracyte Inc
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Veracyte Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Veracyte Inc
NASDAQ:VCYT
Non-Reccuring Items
-$32.7m
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Non-Reccuring Items
-$1.6B
CAGR 3-Years
-7%
CAGR 5-Years
25%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Non-Reccuring Items
-$10B
CAGR 3-Years
-242%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Non-Reccuring Items
$243m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Non-Reccuring Items
-$4.6B
CAGR 3-Years
N/A
CAGR 5-Years
-175%
CAGR 10-Years
-51%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Non-Reccuring Items
-$219.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-35%
No Stocks Found

Veracyte Inc
Glance View

Market Cap
3.1B USD
Industry
Biotechnology

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 761 full-time employees. The company went IPO on 2013-10-30. The firm offers customized biomarker testing and analytical services. The company offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. The company offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. The company also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.

VCYT Intrinsic Value
17.18 USD
Overvaluation 57%
Intrinsic Value
Price

See Also

What is Veracyte Inc's Non-Reccuring Items?
Non-Reccuring Items
-32.7m USD

Based on the financial report for Sep 30, 2024, Veracyte Inc's Non-Reccuring Items amounts to -32.7m USD.

What is Veracyte Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 3Y
-21%

Over the last year, the Non-Reccuring Items growth was 10%. The average annual Non-Reccuring Items growth rates for Veracyte Inc have been -21% over the past three years .

Back to Top